Can This Beaten-Down Cathie Wood Stock Bounce Back?

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.Equities are still in a bull run. The S&P 500 is up by 22% so far in 2024. Not every company has come along for the ride, though. Exact Sciences (EXAS 0.96%), a cancer-focused biotechnology company, has seen its shares drop by 4% year to date.However, the stock does remain a holding of Cathie Wood's investment management firm, Ark Invest -- albeit a small one, as of this writ ...